

CardiacSense Ltd – January 21 report

1. Regulation:

a. Atrial Fibrillation

- i. **CE Mark:** We expect to get it within this month
- ii. **FDA:** we are in process of preparing the additional clinical trial needed in the USA.

2. Clinical trials:

a. 5 clinical trials are being conducted in parallel in Israel:

- i. Respiratory rate that is going to be submitted to the FDA.
We aim to submit the report to the FDA in Q2 2021.
- ii. Early COPD and heart failure deterioration detection
Being conducted at Ichilov
- iii. Arrhythmias detection is being conducted at Rambam hospital
- iv. 2 blood pressure tests at Ichilov hospital. These clinical tests are going slowly due to COVID-19 but still data is collected.

b. Clinical trials in the US:

- i. Oxygen saturation (SpO2) trial will be conducted in UCSF
- ii. Blood pressure tests will be conducted in Colorado
- iii. AF detection Trial in NYU

3. R&D:

Our R&D team efforts revolve around the new hardware version watch (V12.1) that is our first commercial watch. There are still mechanical, hardware and firmware tasks to complete. With that said, we aim to start shipping first watches in Q2 this year.

4. Production:

There is a lot of engineering work regarding the transition from development to production. The production of the watch started in the manufacturing site last year and in the coming months we are expected to get the first series of the watches. If all goes well the next production series of 3,000 watches will be produced and shipped on Q2.

We have placed orders of 40,000 units to be supplied during coming 12 months.

5. **Business development:** we are communicating with few companies that are potential partners for strategic co-operation. We hope that one of these communications will mature in the coming quarter.

6. **Finance and commercial**

a. The \$2M round of \$70M pre-money is completed.

b. Distributors backlog orders has crossed \$90M

c. The company got offers from few underwriters for going public in Tel Aviv Stock Exchange.

The company has started writing the prospectus and planning to go public in Q2/Q3 this year.

In parallel, the company is exploring other venues for fund raising.